FDG-PET在轻度认知障碍临床诊断中的临床效用
本文报告了[18F]氟脱氧葡萄糖(FDG)-PET在支持轻度认知障碍(MCI)受试者中前驱期阿尔茨海默病(AD)、额颞叶变性(FTLD)和前驱期路易体痴呆(DLB)诊断的准确性研究质量,并给出专家组的推荐意见。共纳入54篇论文,FDG-PET在检测MCI due to AD方面具有公平证据水平的临床效用,在FTLD和DLB方面虽有前景但需更多研究。
要点
- FDG-PET在检测MCI due to AD方面具有公平证据水平的临床效用。
- 支持MCI due to AD诊断的临床结局研究显示准确性范围为58%至100%,ROC曲线下面积范围为0.66至0.97。
- 未检索到MCI due to FTLD或MCI due to DLB的相应数据。
核心结论
- FDG-PET在检测MCI due to AD方面具有公平证据水平的临床效用。
- 尽管FDG-PET在检测MCI due to FTLD和MCI due to DLB方面也有前景,但需要更多研究来最终判断FDG-PET在这些疾病中的临床效用。
研究设计与样本
- 由七名专家组成员(其中四名来自欧洲核医学协会,三名来自欧洲神经病学学会)基于德尔菲轮次达成共识推荐。
- 使用统一的人群、干预、比较和结局(PICO)检索字符串进行文献检索,并提供与欧洲神经病学学会联合会指南一致的资金评估。
- 共54篇论文报告了感兴趣的比较。
主要发现
- 所选论文允许识别表征MCI due to AD、FTLD和DLB的FDG模式。
- 支持MCI due to AD诊断的临床结局研究显示准确性范围为58%至100%,ROC曲线下面积范围为0.66至0.97。
- 未检索到MCI due to FTLD或MCI due to DLB的相应数据。
- FDG-PET的高阴性预测值和存在不同的疾病特异性低代谢模式支持该影像技术在MCI受试者中临床使用的共识推荐。
关键数值与推荐
- FDG-PET在检测MCI due to AD方面具有公平证据水平的临床效用。
- 支持MCI due to AD诊断的临床结局研究显示准确性范围为58%至100%,ROC曲线下面积范围为0.66至0.97。
临床怎么用
- 专家组基于德尔菲轮次达成共识推荐,支持FDG-PET在MCI受试者中的临床使用。
局限性
- 支持MCI due to AD诊断的临床结局研究显示准确性范围宽泛(58%至100%),ROC曲线下面积范围宽泛(0.66至0.97)。
- 未检索到MCI due to FTLD或MCI due to DLB的相应数据。
- 需要更多研究来最终判断FDG-PET在MCI due to FTLD和MCI due to DLB中的临床效用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We aim to report the quality of accuracy studies investigating the utility of [18F]fluorodeoxyglucose (FDG)-PET in supporting the diagnosis of prodromal Alzheimer's Disease (AD), frontotemporal lobar degeneration (FTLD) and prodromal dementia with Lewy bodies (DLB) in mild cognitive impairment (MCI) subjects, and the corresponding recommendations made by a panel of experts. METHODS: Seven panellist, four from the European Association of Nuclear Medicine, and three from the European Academy of Neurology, produced recommendations taking into consideration the incremental value of FDG-PET, as added on clinical-neuropsychological examination, to ascertain the aetiology of MCI (AD, FTLD or DLB). A literature search using harmonized population, intervention, comparison, and outcome (PICO) strings was performed, and an evidence assessment consistent with the European Federation of Neurological Societies guidance was provided. The consensual recommendation was achieved based on Delphi rounds. RESULTS: Fifty-four papers reported the comparison of interest. The selected papers allowed the identification of FDG patterns that characterized MCI due to AD, FTLD and DLB. While clinical outcome studies supporting the diagnosis of MCI due to AD showed varying accuracies (ranging from 58 to 100%) and varying areas under the receiver-operator characteristic curves (0.66 to 0.97), no respective data were identified for MCI due to FTLD or for MCI due to DLB. However, the high negative predictive value of FDG-PET and the existence of different disease-specific patterns of hypometabolism support the consensus recommendations for the clinical use of this imaging technique in MCI subjects. CONCLUSIONS: FDG-PET has clinical utility on a fair level of evidence in detecting MCI due to AD. Although promising also in detecting MCI due to FTLD and MCI due to DLB, more research is needed to ultimately judge the clinical utility of FDG-PET in these entities.
引用
- Arbizu J, Festari C, Altomare D, et al. Clinical utility of FDG-PET for the clinical diagnosis in MCI. Eur J Nucl Med Mol Imaging. 2018. PMID: 29704037. doi:10.1007/s00259-018-4039-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。